Hims stock is climbing back from a steep drop within a base. Shares have climbed nearly 29% during the month and outperformed ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Shares of Hims Hers Health Inc (NYSE:HIMS) fell more than 3% early Tuesday before paring losses to around 0.2% in afternoon trade, after rising legal risks and a data disclosure drove swings in ...

Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

The more cautious voices point to Hims’s high P/E ratio and recent volatility, warning that the stock could cool off after its sharp run-up. That said, a few analysts are still pretty optimistic. They ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs. These drugs are ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Hims & Hers Health (HIMS -1.19%) is a telehealth company that offers personalized solutions for its customers. And demand has been robust, with subscriptions for its products risi ...

Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...